Trial Profile
LUX-Lung IO: A Phase II, Open Label, Non-randomised Study of Afatinib in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Keynote 497; LUX-Lung IO
- Sponsors Boehringer Ingelheim
- 01 Apr 2022 Status was changed to discontinued, according to Results published in the Lung Cancer.
- 01 Apr 2022 Results published in the Lung Cancer
- 29 Oct 2019 Planned End Date changed from 27 Apr 2020 to 18 Jun 2020.